Legal Epidemiology: The Science of Law

Abstract

The importance of legal epidemiology in public health law research has undoubtedly grown over the last five years. Scholars and practitioners together have developed guidance on best practices for the field, including: placing emphasis on transdisciplinary collaborations; creating valid, reliable, and repeatable research; and publishing timely products for use in decision-making and change. Despite the energy and expertise researchers have brought to this important work, they name significant challenges in marshalling the diverse skill sets, quality controls, and funding to implement legal epidemiology activities. The Centers for Disease Control and Prevention (CDC) has worked to develop cross-cutting research and translation on issues of national priority in legal epidemiology, and has explored ways to overcome some of these challenges. As such, this article describes a case study of the use of law to characterize states' prior authorization policies regarding medication used to treat attention-deficit/hyperactivity disorder (ADHD), a central component of a broader effort to improve behavior therapy options for young children with ADHD. This article highlights the types of legal epidemiology work we have undertaken, the application of this work to an emerging public health problem, and the lessons learned in creating impactful research for the field.

Get full access to this article

View all access options for this article.

References

T. R.

Frieden

, “A Framework for Public Health Action: The Health Impact Pyramid,” American Journal of Public Health 100, no. 4 (2010): 590-595.

Pepin

et al ., “Collaborating for Health: Health in All Policies and the Law,” Journal of Law, Medicine & Ethics 45, no. 1, Supp. (2017): 60-64.

Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies, For the Public's Health: Investing in a Healthier Future, 2012, available at <https://www.nap.edu/catalog/13268/for-the-publics-health-investing-in-a-healthier-future> (last visited January 23, 2017).

Presley

et al ., Resources for Policy Surveillance, Technical Standards for Policy Surveillance and Legal Datasets: Report of a Delphi Process, available at <http://publichealthlawre-search.org/sites/default/files/uploaded_images/CombinedYear1Report_Feb2015.pdf> (last visited January 23, 2017).

Burris

et al ., “A Transdisciplinary Approach to Public Health Law: The Emerging Practice of Legal Epidemiology,” Annual Review of Public Health 37 (2016): 135-148.

Martini

et al ., Scan of CDC Legal Epidemiology Articles, 2011-2015, available at <http://publichealthlawresearch.org/sites/default/files/downloads/product/CDCLegalEpidemiologyPublicationsScan_FINALOct2015.pdf> (last visited January 23, 2017).

Burris

et al ., “Policy Surveillance: A Vital Public Health Practice Comes of Age,” Journal of Health Politics, Policy and Law 41, no. 6 (2016): 1061-1083.

Burris

et al ., “Moving from Intersection to Integration: Public Health Law Research and Public Health Systems and Services Research,” The Milbank Quarterly 90, no. 2 (2012): 375-408.

Agency for Healthcare Research and Quality, Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers; Long-Term Effectiveness in All Ages; and Variability in Prevalence, Diagnosis, and Treatment (2011), available at <https://effectivehealthcare.ahrq.gov/ehc/products/191/814/CER44_ADHD_ExecSumm_20111021.pdf> (last visited January 23, 2017).

10.

S. N.

Visser

et al ., “Trends in the Parent-Report of Health Care Provider-Diagnosed and Medicated Attention-Deficit/Hyperactivity Disorder: United States, 2003–2011,” Journal of the American Academy of Child & Adolescent Psychiatry 53, no. 1 (2014): 34-46.e2.

11.

Id.

12.

Id.

13.

S. N.

Visser

et al ., “Vital Signs: National and State-Specific Patterns of Attention Deficit/Hyperactivity Disorder Treatment among Insured Children Aged 2-5 Years - United States, 2008-2014,” Morbidity and Mortality Weekly Report 65, no. 17 (2016): 443-450.

14.

Charach

et al ., “Interventions for Preschool Children at High Risk for ADHD: A Comparative Effectiveness Review,” Pediatrics 131, no. 5 (2013): e1584-e1604.

15.

American Academy of Pediatrics, “ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,” Pediatrics 128, no. 5 (2011): 1007-1022.

16.

See supra note 13.

17.

Anderson

et al ., “Measuring Statutory Law and Regulations for Empirical Research,” in

A. C.

Wagenaar , and

Burris , eds., Public Health Law Research: Theory and Methods (San Francisco, CA: Jossey-Bass, 2013): at 237-260.

18.

Hulkower

et al ., “50-State Assessment of Medicaid Prior-Authorization Policies for Medication Treatment of ADHD in Young Children” (forthcoming 2017).

19.

Prior Authorization Policies for Pediatric ADHD Medication Prescriptions, “LawAtlas: The Policy Surveillance Portal,” available at <http://lawatlas.org/datasets/adhd-prior-authorization-policies> (last visited February 16, 2017).